There is a number on a member's lipid panel that the standard physician's note rarely mentions, that the standard insurance billing code does not require, and that — if it is high — predicts heart disease more precisely than any other single value on the report. Apolipoprotein B. ApoB. The protein that decorates every atherogenic lipid particle in the bloodstream. One per particle. Count the protein, count the particles. Count the particles, predict the risk.
The reason most members have never had it measured is structural. The standard panel measures cholesterol — the lipid cargo — and infers risk from how much cargo is being carried. ApoB measures the trucks. For most populations the cargo and the truck count are correlated and the standard panel is roughly right. For a meaningful minority, particularly the metabolically lean and the metabolically inflamed, the two diverge sharply, and the cargo number lulls the patient and physician into thinking risk is lower than it is.
What the particle is, said cleanly
Cholesterol does not float free in the blood. It travels in lipoprotein particles — spherical packages with cholesterol and triglyceride inside, phospholipid membrane outside, and a single defining protein on the surface that tells the body what the particle is and where it is going. ApoB is the marker on every particle that contributes to plaque: VLDL, IDL, LDL, and Lp(a). Each of those particles carries one ApoB molecule. If you are circulating one billion atherogenic particles, you are circulating one billion ApoB molecules. The math is exactly that clean.
HDL, the so-called good cholesterol, carries a different surface protein — ApoA-I — and is not counted in ApoB. The atherogenic risk equation, in modern lipidology, is essentially a question of how many ApoB-bearing particles are circulating in a member's bloodstream and for how many years.
Why LDL-C undersells the risk in some patients
LDL cholesterol — the LDL-C number on the standard panel — is the cholesterol content of the LDL particles. It is calculated, in most cases, not directly measured. When the particles are large and cholesterol-rich, the panel tells you a true story: high LDL-C means many particles or large particles, both of which are problematic.
When the particles are small and cholesterol-poor — a phenotype seen in metabolic syndrome, pre-diabetes, and the inflammatory aftermath of a poor diet — the same number of particles carries less cholesterol. LDL-C looks reassuring. Particle count is unchanged. ApoB is unchanged. Risk is unchanged or worse, because small dense particles also penetrate the arterial wall more readily than large buoyant ones.
The clean way to put it: LDL-C measures the weight of the trucks. ApoB counts them. If your trucks are loaded with refrigerators, the weight tells you the count. If your trucks are loaded with envelopes, the weight is silent on how many are on the road.
What the threshold is, in 2026
The European Atherosclerosis Society and the National Lipid Association have converged in recent years on threshold language that translates roughly as follows. For an asymptomatic adult at average risk, ApoB below 90 mg/dL is reasonable; below 80 mg/dL is preferable. For an adult with elevated risk — family history of premature coronary disease, diabetes, hypertension, prior event — the target moves down. Below 70 mg/dL for elevated risk, below 60 mg/dL for very high risk, and below 50 mg/dL for the secondary-prevention population whose first cardiovascular event has already occurred and whose job is now to prevent the second.
These numbers are not magic. They are the inflection points at which the relationship between ApoB and event rates begins to bend favorably in the long-term cohort data. Lower is better, in a continuous and dose-response way, down to thresholds we now believe are biologically uncomplicated even when achieved pharmacologically.
What our members get measured
The intake panel for our longevity-curious members includes ApoB as a standing line item. We also pull Lp(a) once in a member's lifetime, because it is genetically determined and does not require repeat testing once known. Lp(a) is, in our experience, the single most actionable surprise on the panel; roughly one in five members has elevated Lp(a) they did not know about, and the elevation changes the long-term plan.
We do not run a particle-count NMR by default. The newer studies suggest ApoB and direct LDL-particle counts converge tightly enough that the simpler, cheaper assay is the right line for the standard member. We reserve the NMR for the populations where it changes the next decision — usually members in whom ApoB and LDL-C disagree by enough that we want to verify the divergence before acting on it.
What you do with the number
The list of inputs that move ApoB downward is short and well-supported. Saturated fat reduction in the diet, particularly the swap from animal fats to monounsaturated and polyunsaturated sources, has a small-to-moderate effect on most patients. Soluble fiber, particularly from oats, beans, and certain whole-grain sources, modestly reduces ApoB through the bile-acid pathway. Body fat loss, particularly visceral adipose, reduces VLDL secretion and pulls ApoB down with it. Aerobic exercise, sustained at conversational intensity, reduces ApoB modestly through hepatic mechanisms that are still being mapped but that converge on insulin sensitivity and triglyceride handling.
The pharmacologic options are what they have always been — statins as the first-line evidence-based intervention, ezetimibe as an additive second line, PCSK9 inhibitors and bempedoic acid where the response to first-line is insufficient, and, in highly selected populations, the newer therapeutics whose long-term outcome data are still maturing. The decisions live with the member's primary care physician or cardiologist; we are an evidence-aware longevity facility, not a prescriber.
What we do, on our floor, is the lifestyle layer. The Zone 2 protocol on the bike. The Mediterranean-leaning plate model in our nutrition consult. The body-composition work that pulls visceral fat down without sacrificing lean mass. These do not replace pharmacology where it is indicated. They make the next decision smaller, slower, and easier to live with.
The honest framing
Cardiovascular disease remains the leading cause of death in adults. The risk is overwhelmingly determined by ApoB-particle exposure integrated over time — the number of years a member's bloodstream carries above-threshold particle counts. A member who corrects ApoB at fifty has bought themselves a different decade than the same member who corrects at sixty-five. The decade between those two moments is the decade in which atherosclerotic plaque becomes calcified, stable, and harder to reverse.
The conversation we have with members — once, in the consultation, with the lab in front of us — is about that decade. What is your number now. What can it be. What is the cleanest path between the two that respects the rest of your life. And how do we measure the answer in twelve weeks.
That is the cholesterol conversation worth having. The standard one, in our view, has under-served patients for a generation.
— Published in The Bioneer, Journal.